|Day Low/High||2.16 / 2.27|
|52 Wk Low/High||1.99 / 5.05|
Our portfolio fell along with the broader market (especially small-caps), but there were some bright spots as well.
Here's our current thinking on AcelRx Pharmaceuticals, Antares Pharma, CPI Aerostructures and Pareteum.
While the portfolio experienced some pain last week along with the broader market, 12 of our holdings beat the Russell 2000 either on an absolute or relative basis.
51 REMS-certified facilities and 43 formulary approvals since launch
We exited a position last week for a nice gain as the market continued to rise.
Investors in AcelRx Pharmaceuticals Inc saw new options begin trading this week, for the March 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
As the momentum of earnings season rose last week, we made several trades including initiating a new position in Innovative Solutions and Support.
We added to one position last week as as the small-cap heavy Russell 2000 dipped.
We added to one position and initiated another during a shortened holiday week.
We initiated a new position and added to a couple of others as we closed the books on the second quarter.
REDWOOD CITY, Calif., July 1, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
Last week we started two new positions, trimmed a winner and exited another name as the markets moved higher across the board.
With the market rising last week, we saw favorable action in several of our holdings and booked some hefty gains in one name.
With the market rebounding, the majority of our positions rose week over week.
During the week, we exited our position in KushCo Holdings and initiated Antares Pharma.
REDWOOD CITY, Calif., June 3, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
Several positive moves along with our cash position helped insulate the overall portfolio’s performance from last week's market decline.
Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACRX options chain for the new July 19th contracts and identified the following put contract of particular interest.
Amid renewed trade and geopolitical tensions, we trimmed our position in Energy Recovery and added a short-term trade in J.C. Penney.
We took some nice profits trimming a position, exited a name and added to another holding during a challenging week for stocks.
REDWOOD CITY, Calif., May 8, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
We added to three positions and pulled the plug on another during a solid week for small-cap stocks.
We ditched one position and added to another last week as small-cap stocks trended higher.
Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
REDWOOD CITY, Calif., April 25, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
During the week, we took a starter position in Encana Corp. and boosted our cash position by trimming iShares Russell 2000 ETF.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.